Premium
Polypyridyl Ruthenium(II) Complexes with Red‐Shifted Absorption: New Promises in Photodynamic Therapy
Author(s) -
Banerjee Samya
Publication year - 2021
Publication title -
chembiochem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.05
H-Index - 126
eISSN - 1439-7633
pISSN - 1439-4227
DOI - 10.1002/cbic.202100102
Subject(s) - photodynamic therapy , holy grail , absorption (acoustics) , ruthenium , chemistry , in silico , in vivo , red light , photochemistry , combinatorial chemistry , nanotechnology , materials science , computer science , biochemistry , organic chemistry , catalysis , biology , botany , microbiology and biotechnology , world wide web , composite material , gene
In the field of cancer photodynamic therapy (PDT) research, development of metal‐based PDT drugs that can be used under red light exposure is the “holy grail” to achieve. This highlight highlighted few current literatures on polypyridyl‐based Ru(II) complexes with significantly red‐shifted absorption to achieve in‐vitro and in‐vivo PDT effect in 540–600 nm light. The enormous potential of judicial ligand choice and in ‐ silico optimization to achieve the red light, metal‐based PDT drugs are discussed.